drugset
drugset / Trial / NCT04598009

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

NCT04598009 ↗

Phase 2 Recruiting 25 enrolled University of California, San Francisco Array BioPharma · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.

Timeline

Start
2021-03-03
Primary completion
2027-05-31
Completion
2028-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Binimetinib Small molecule — Oral
Subject Imatinib Small molecule — Oral

Indications

melanoma